Therapeutic effect of aswagandhadi compound in asthi-majja kshaya (osteoporosis/osteopenia) - A Pilot Study
International Journal of Development Research
Therapeutic effect of aswagandhadi compound in asthi-majja kshaya (osteoporosis/osteopenia) - A Pilot Study
Received 14th August 2017; Received in revised form 26th September, 2017; Accepted 21st October, 2017; Published online 12th November, 2017
Copyright © 2017, DipSundar Sahu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Osteoporosis is a systemic disorder that affects entire skeleton, which is a metabolic disease of the bone characterized by low bone mass and micro architectural deterioration of the skeleton, leading to enhanced bone fragility and fracture risk. In Ayurveda, it is correlated with Asthi-Majjakshaya. Basing on the concept a formulation “Aswagandhadi Compound” has been selected to observe the possibility of enhancement of bone mass and 30 numbers of patients for 4 weeks, on the basis of symptomatology and confirmed BMD test at Indoor Patients Department (IPD) were put to observational study of National Research Institute of Ayurved Drug Development, Bhubaneswar. It was observed that, BMD (t-score) was increased by 4.3% after completion of treatment duration, which was statistically highly significant (P<0.001). It was observed that the drug is able to enhance the bone cell formation as well as decreasing bone mass desorption. The formulation expected to act by balancing bone remodeling and also preventing bone loss by increasing the bone density. It is interpreted from the above study that, this “Aswagandhadi Compound” is having efficacy on the disease Asthi-Majjakshaya (Osteoporosis/Osteopenia) from the evidence of the study which is discussed in details.